Genelux begins dosing in Phase II ovarian cancer trial

US-based oncolytic immunotherapy developer Genelux has started dosing patients in a Phase II clinical trial (VIRO-15) of its clinical-stage candidate GL-ONC1 to treat recurrent ovarian cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Contributors : Juan R Cubillos-Ruiz ; Minkyung SongSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusTumors evade immune control by creating hostile microenvironments that perturb T cell metabolism and effector function. However, it remains unclear how intratumoral T cells integrate and interpret metabolic stress signals. Here we report that ovarian cancer (OvCa), an aggressive malignancy refractory to standard treatments and current immunotherapies, induces Endoplasmic Reticulum (ER) stress and activation of the IRE1 α-XBP1 arm of the Unfolded Protein Response (UPR)10,11 in T cel...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
Abstract The field of cancer immunology stepped into the limelight this year when James P. Allison and Tasuku Honjo received the Nobel Prize in Physiology or Medicine for their discovery of cancer therapy by inhibition of negative immune regulation. Among many exciting advances contributing to the coming of age of tumour immunology as a viable clinical specialty has been the ability to progress from the initial elucidation of tumour antigens, such as the melanoma antigen, MAGE-1, to high-throughput sequencing facilitating identification of T cell epitopes from diverse tumour neoantigens. This has resulted from the...
Source: Immunology - Category: Allergy & Immunology Authors: Tags: Immunology Source Type: research
Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Source Type: research
University of Leicester researchers soon will open the first molecularly stratified clinical trial for malignant mesothelioma with the hope of moving the future of treatment toward more personalization. The phase II trial in the United Kingdom is designed to match therapy with a patient’s specific genetic profile. “We’re trying to bring the right drug to the right patient at the right time,” Professor Dean Fennell, chair of thoracic medical oncology at Leicester and chief trial investigator, told Asbestos.com. “We need to find different treatments that work for different people. This is a step...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
AbstractDendritic cell (DC)-based immunotherapies have been created for a broad expanse of cancers, and DC vaccines prepared with Wilms ’ tumor protein 1 (WT1) peptides have shown great therapeutic efficacy in these diseases. In this paper, we report the results of a phase I/II study of a DC-based vaccination for advanced breast, ovarian, and gastric cancers, and we offer evidence that patients can be effectively vaccinated with a utologous DCs pulsed with WT1 peptide. There were ten patients who took part in this clinical study; they were treated biweekly with a WT1 peptide-pulsed DC vaccination, with toxicity and c...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
CONCLUSION: Although the expression of PD-L1 and immune checkpoint markers in residual tumors after NAC had no prognostic impact on survival in patients with HGSOC, post-NAC evaluation of these proteins in chemoresistant tumors may help select patients for immunotherapy trials. PMID: 30314669 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
Publication date: Available online 1 October 2018Source: Hematology/Oncology Clinics of North AmericaAuthor(s): Thinle Chodon, Amit A. Lugade, Sebastiano Battaglia, Kunle Odunsi
Source: Hematology Oncology Clinics of North America - Category: Hematology Source Type: research
A new proteomic analysis found that CT45 is an independent prognostic factor in patients with high-grade serous ovarian cancer, and a potential target of immunotherapies.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
AbstractEpithelial ovarian cancer (EOC) is the leading cause of gynaecological cancer-related death in Europe. Although most patients achieve an initial complete response with first-line treatment, recurrence occurs in more than 80% of cases. Thus, there is a clear unmet need for novel second-line treatments. EOC is frequently infiltrated with T lymphocytes, the presence of which has been shown to be associated with improved clinical outcomes. Adoptive T-cell therapy (ACT) using ex vivo-expanded tumour-infiltrating lymphocytes (TILs) has shown remarkable efficacy in other immunogenic tumours, and may represent a promising ...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Epithelial ovarian cancer (EOC) cells are known to shield themselves from immunosurveillance by secreting immune inhibitory cytokines such as IL-10. Using mesothelin, a differentiating antigen that is overexpressed in EOC, we assessed the effect of the tumor microenvironment on chimeric antigen receptor (CAR) T cell-based immunotherapy and its reversal via IL-10 depletion.
Source: Journal of the American College of Surgeons - Category: Surgery Authors: Tags: Scientific poster presentations Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Immunotherapy | Ovarian Cancer | Ovaries | Pharmaceuticals